Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The results could also be relevant for people with other types of HER2-low cancer.
The antibody-drug conjugate improved progression-free and overall survival for patients with low HER2 expression on breast tumors.
Researchers at Dana-Farber Cancer Institute show that “HER2-low” tumors are not a distinct subtype of breast cancer.
Artificial intelligence and machine learning can help identify genetic changes that lead to cancer—and which treatments work best.
The new cancer subtypes help better characterize a person’s tumor. The goal is to get the right drug to the right patient.
A look at the symptoms, treatments, risk factors, prognosis and research on breast cancer metastasis to the brain.
Here are latest cancer drugs approved by the Food and Drug Administration.
Monoclonal antibody delays disease progression in people with previously treated HER2-positive tumors.
The honeybee’s sting contains a compound that kills hard-to-treat breast cancer cells quickly.
The oral targeted therapy lowered the risk of relapse in a late-stage study.
Here are latest arrivals approved by the Food and Drug Administration.
New injectable combination can be administered by health care providers outside medical centers.
A new randomized study sought to clarify results from previous studies that suggested there would be a benefit from such local treatment.
Last year, the FDA approved three new antibody-drug conjugates for treating cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.